全文获取类型
收费全文 | 1381740篇 |
免费 | 101395篇 |
国内免费 | 6120篇 |
专业分类
耳鼻咽喉 | 20174篇 |
儿科学 | 40924篇 |
妇产科学 | 39571篇 |
基础医学 | 192032篇 |
口腔科学 | 40728篇 |
临床医学 | 118371篇 |
内科学 | 268589篇 |
皮肤病学 | 30813篇 |
神经病学 | 108302篇 |
特种医学 | 55992篇 |
外国民族医学 | 469篇 |
外科学 | 213987篇 |
综合类 | 39801篇 |
现状与发展 | 21篇 |
一般理论 | 450篇 |
预防医学 | 94962篇 |
眼科学 | 32610篇 |
药学 | 105807篇 |
53篇 | |
中国医学 | 5963篇 |
肿瘤学 | 79636篇 |
出版年
2018年 | 13666篇 |
2017年 | 11317篇 |
2016年 | 12290篇 |
2015年 | 14253篇 |
2014年 | 19715篇 |
2013年 | 28254篇 |
2012年 | 37238篇 |
2011年 | 39377篇 |
2010年 | 23657篇 |
2009年 | 22626篇 |
2008年 | 36737篇 |
2007年 | 39884篇 |
2006年 | 40239篇 |
2005年 | 38789篇 |
2004年 | 37306篇 |
2003年 | 36090篇 |
2002年 | 35358篇 |
2001年 | 64874篇 |
2000年 | 66442篇 |
1999年 | 56212篇 |
1998年 | 14531篇 |
1997年 | 13313篇 |
1996年 | 12676篇 |
1995年 | 12633篇 |
1994年 | 11837篇 |
1992年 | 43104篇 |
1991年 | 41580篇 |
1990年 | 40802篇 |
1989年 | 39773篇 |
1988年 | 37140篇 |
1987年 | 36579篇 |
1986年 | 35028篇 |
1985年 | 33205篇 |
1984年 | 24861篇 |
1983年 | 21047篇 |
1982年 | 12649篇 |
1981年 | 11555篇 |
1979年 | 23911篇 |
1978年 | 17040篇 |
1977年 | 14777篇 |
1976年 | 13348篇 |
1975年 | 15231篇 |
1974年 | 18065篇 |
1973年 | 17562篇 |
1972年 | 16817篇 |
1971年 | 15715篇 |
1970年 | 14894篇 |
1969年 | 14337篇 |
1968年 | 13453篇 |
1967年 | 11997篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
21.
Stephanie H. Ameis John D. Haltigan Rachael E. Lyon Amanda Sawyer Pat Mirenda Connor M. Kerns Isabel M. Smith Tracy Vaillancourt Joanne Volden Charlotte Waddell Lonnie Zwaigenbaum Teresa Bennett Eric Duku Mayada Elsabbagh Stelios Georgiades Wendy J. Ungar Anat Zaidman-Zait Meng-Chuan Lai Peter Szatmari for the Pathways in ASD Study Team 《Journal of child psychology and psychiatry, and allied disciplines》2022,63(5):553-562
22.
淫羊藿是一种常用的中药材,淫羊藿苷是从淫羊藿中提取的一种黄酮类化合物,也是淫羊藿中最主要的活性物质。研究发现,淫羊藿苷具有促进成骨细胞的生成和活化、调节免疫、抗衰老和抗炎等多种功能。临床上淫羊藿(苷)用于治疗生殖系统、骨关节系统、呼吸系统、神经系统、心血管系统和免疫系统等多种疾病。淫羊藿(苷)对男性生殖系统的作用及机制主要包括具有雄性激素样作用,促进睾内睾酮的合成和分泌。淫羊藿(苷)通过改善精子发生的微环境、增强睾丸抗氧化作用促进精子生成,增加精子密度,改善精子活力,减缓生殖衰退。此外,淫羊藿(苷)可促进阴茎勃起,治疗勃起功能障碍及早泄。 相似文献
23.
24.
Patrick Demkowicz BS Renelle Pointdujour-Lim MD Sofia Miguez BA Yesung Lee BS Bailey S. C. L. Jones BS Christopher A. Barker MD Marcus Bosenberg MD PhD David H. Abramson MD Alexander N. Shoushtari MD Harriet Kluger MD Jasmine H. Francis MD Mario Sznol MD Mathieu F. Bakhoum MD PhD 《Cancer》2023,129(20):3275-3286
25.
Tianshu Liu Yuxian Bai Xiaoyan Lin Wei Li Jufeng Wang Xiaochun Zhang Hongming Pan Chunmei Bai Li Bai Ying Cheng Jingdong Zhang Haijun Zhong Yi Ba Wenwei Hu Ruihua Xu Weijian Guo Shukui Qin Nong Yang Jianwei Lu Kohei Shitara Ming Lei Mingshun Li Nicole Bao Tian Chen Lin Shen 《International journal of cancer. Journal international du cancer》2023,152(4):749-760
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC. 相似文献
26.
Eileen M. Dryden PhD Meaghan A. Kennedy MD MPH Jennifer Conti MPH Jacqueline H. Boudreau MPH Chitra P. Anwar MA Kathryn Nearing PhD MA Camilla B. Pimentel PhD MPH William W. Hung MD MPH Lauren R. Moo MD 《Health services research》2023,58(Z1):26-35
Objective
Explore the perceived benefits of a Veterans Health Administration (VHA) geriatric specialty telemedicine service (GRECC Connect) among rural, older patients and caregivers to contribute to an assessment of its quality and value.Data Sources
In Spring 2021, we interviewed a geographically diverse sample of rural, older patients and their caregivers who participated in GRECC Connect telemedicine visits.Study Design
A cross-sectional qualitative study focused on patient and caregiver experiences with telemedicine, including perceived benefits and challenges.Data Collection
We conducted 30 semi-structured qualitative interviews with rural, older (≥65) patients enrolled in the VHA and their caregivers via videoconference or phone. Interviews were recorded, transcribed, and analyzed using a rapid qualitative analysis approach.Principal Findings
Participants described geriatric specialty telemedicine visits focused on cognitive assessments, tailored physical therapy, medication management, education on disease progression, support for managing multiple comorbidities, and suggestions to improve physical functioning. Participants reported that, in addition to prescribing medications and ordering tests, clinicians expedited referrals, coordinated care, and listened to and validated both patient and caregiver concerns. Perceived benefits included improved patient health; increased patient and caregiver understanding and confidence around symptom management; and greater feelings of empowerment, hopefulness, and support. Challenges included difficulty accessing some recommended programs and services, uncertainty related to instructions or follow-up, and not receiving as much information or treatment as desired. The content of visits was well aligned with the domains of the Age-Friendly Health Systems and Geriatric 5Ms frameworks (Medication, Mentation, Mobility, what Matters most, and Multi-complexity).Conclusions
Alignment of patient and caregiver experiences with widely-used models of comprehensive geriatric care indicates that high-quality geriatric care can be provided through virtual modalities. Additional work is needed to develop strategies to address challenges and optimize and expand access to geriatric specialty telemedicine. 相似文献27.
Two-year results after combined phacoemulsification and iris-fixated phakic intraocular lens removal
Gaurisankar Zoraida Solaiga van Rijn Gwyneth A. Cheng Yanny Y. Y. Luyten Gregorius P. M. Beenakker Jan-Willem M. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(4):1367-1375
Graefe's Archive for Clinical and Experimental Ophthalmology - To describe and present results after a technique for cataract surgery combined with explantation of an iris-fixated phakic... 相似文献
28.
29.
30.
Carlton Corinne N. Garcia Katelyn M. Andino Mara Villalongo Ollendick Thomas H. Richey John A. 《Cognitive therapy and research》2022,46(5):916-926
Cognitive Therapy and Research - Individuals with Social Anxiety Disorder (SAD) may be at a higher risk for negative outcomes during the COVID-19 pandemic due to isolation that is both... 相似文献